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Ebola viruses are highly lethal human pathogens that have received considerable attention in recent years due to an
increasing re-emergence in Central Africa and a potential for use as a biological weapon. There is no vaccine or
treatment licensed for human use. In the past, however, important advances have been made in developing preventive
vaccines that are protective in animal models. In this regard, we showed that a single injection of a live-attenuated
recombinant vesicular stomatitis virus vector expressing the Ebola virus glycoprotein completely protected rodents
and nonhuman primates from lethal Ebola challenge. In contrast, progress in developing therapeutic interventions
against Ebola virus infections has been much slower and there is clearly an urgent need to develop effective post-
exposure strategies to respond to future outbreaks and acts of bioterrorism, as well as to treat laboratory exposures.
Here we tested the efficacy of the vesicular stomatitis virus-based Ebola vaccine vector in post-exposure treatment in
three relevant animal models. In the guinea pig and mouse models it was possible to protect 50% and 100% of the
animals, respectively, following treatment as late as 24 h after lethal challenge. More important, four out of eight
rhesus macaques were protected if treated 20 to 30 min following an otherwise uniformly lethal infection. Currently,
this approach provides the most effective post-exposure treatment strategy for Ebola infections and is particularly
suited for use in accidentally exposed individuals and in the control of secondary transmission during naturally
occurring outbreaks or deliberate release.
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Introduction
Editor’s Note: The potential efﬁcacy of pre- and post-exposure
prophylaxis against Ebola virus infection, as well as the fundamentally
important question of whether neutralizing antibodies are important
for Ebola virus resistance, is addressed by a related manuscript in this
issue of PLoS Pathogens. Please see doi:10.1371/journal.
ppat.0030009 by Oswald et al.
Infection with the ﬁloviruses, in particular Zaire ebolavirus
(ZEBOV), Sudan ebolavirus, or Marburg virus (MARV), causes a
severe haemorrhagic fever (HF) in humans and nonhuman
primates that is often fatal [1–3]. In addition to the sporadic
outbreaks that have occurred in humans in Central Africa
since 1976 and caused more than 1,800 human infections with
a lethality rate ranging from 53% to 90%, Ebola virus (EBOV)
has also decimated populations of wild apes in this same
region [4]. At this time, there is no preventive vaccine or post-
exposure treatment option available for human use.
Much remains to be learned about these highly virulent
viruses; however, important advances have been made over
the last decade in understanding how ﬁloviruses cause disease
and in developing preventive vaccines that are protective in
nonhuman primates [1,5]. For example, a recombinant
replication-defective adenovirus vaccine completely pro-
tected nonhuman primates from uniformly lethal ZEBOV
infection [6,7]. More recently, we generated live-attenuated
recombinant vesicular stomatitis viruses (VSV) expressing the
transmembrane glycoproteins (GP) of ZEBOV (VSVDG/
ZEBOVGP) and MARV (VSVDG/MARVGP) and the glyco-
protein precursor of Lassa virus (VSVDG/LASVGPC) [8] and
showed that these completely protected cynomolgus mac-
aques against lethal challenge with the corresponding
ﬁloviruses and arenavirus [9,10]. Progress in developing
therapeutic interventions against the ﬁloviruses has been
much slower [5]. Limited success was achieved in using an
anticoagulant to treat EBOV infections [11], and very recently
the VSV-based MARV vaccine platform (VSVDG/MARVGP)
demonstrated astonishing efﬁcacy in post-exposure treat-
ment of MARV-infected macaques [12]. Other than that, no
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primates against lethal ﬁlovirus infections [5,13,14].
There is clearly an urgent need to develop ﬁlovirus-speciﬁc
effective post-exposure strategies to respond to future
outbreaks in Central Africa, to counter acts of bioterrorism,
and to treat laboratory exposures such as the recent EBOV
exposures that occurred in the United States and Russian
laboratories [15,16]. Post-exposure vaccine treatment is
successful in preventing or modifying viral diseases such as
rabies [17,18], hepatitis B [19], and smallpox [20,21] in
humans, as well as MARV HF in nonhuman primates [12].
However, the faster disease course and higher lethality of
ZEBOV in human and nonhuman primates may limit the
success of a similar approach for EBOV HF. Here, we show
remarkable efﬁcacy of the VSV-based EBOV vaccine platform
in the post-exposure treatment of rodents and nonhuman
primates infected with ZEBOV. Currently, this is the most
promising post-exposure treatment strategy for EBOV HF
and is particularly suited for use in accidentally exposed
individuals and in the control of transmission in the event of
natural or deliberate outbreaks.
Methods
Vaccine Vectors and ZEBOV Challenge Viruses
The recombinant VSV expressing the GPs of ZEBOV (strain
Mayinga), MARV (strain Musoke), or Lassa virus (strain Josiah)
weregeneratedasdescribedrecentlyusingtheinfectiousclone
for the VSV, Indiana serotype (kindly provided by J. Rose) [8].
Brieﬂy, the appropriate open reading frames for the GPs
(ZEBOV, Mayinga, MARV, Musoke) were generated by PCR,
cloned into the VSV genomic vectors lacking the VSV G gene,
sequenced, and originally rescued using the method described
earlier[8,22].ZEBOV(strainKikwit)wasisolatedfromapatient
of the EBOV outbreak in Kikwit in 1995 [23]. The mouse- and
guinea pig-adapted ZEBOV strains (MA-ZEBOV and GA-
ZEBOV, respectively) were generated by serial passages in the
different rodent species until uniformly lethal [24,25].
Animal Studies
Rodents. Female BALB/c mice, 5–6 wk old, were purchased
from Charles Rivers (Quebec, Canada). The animals (groups
of ﬁve) were treated by intraperitoneal (i.p.) inoculation of 2
310
5 plaque forming units (pfu) of VSVDG/ZEBOVGP into
the left and right site of the abdomen (100 ll each). Naı ¨ve
control animals were immunized with the same volume of
Dulbecco’s Mimimal Essential Medium (DMEM) by the same
route. The mice were challenged i.p. with 1,000 LD50 of MA-
ZEBOV into the left and right site of the abdomen (100 ll
each). Female guinea pigs (Hartley strain), approximately 250
g, were purchased from Charles Rivers (Quebec, Canada). The
animals (groups of six) were i.p.-treated with 2 3 10
5 pfu of
VSVDG/ZEBOVGP into the left and right site of the abdomen
(500 ll each). Naı ¨ve control animals were immunized with the
same volume of DMEM by the same route. The guinea pigs
were challenged i.p. with 1,000 LD50 of GA-ZEBOV into the
left and right site of the abdomen (500 ll each). All rodents
(mice and guinea pigs) were weighed daily for a minimum of
11 d following challenge and observed for clinical symptoms
according to an approved scoring sheet (rufﬂed fur, slowing
activity, loss of body conditions, labored breathing, hunched
posture, bleeding, paralysis). Surviving animals were kept
three times longer than the death of the last control animal.
All rodent work was performed in the Biosafety Level (BSL)-4
biocontainment facility at the National Microbiology Labo-
ratory of the Public Health Agency of Canada and was
approved by the Canadian Science Centre for Human and
Health Animal Care Committee following the guidelines of
the Canadian Council on Animal Care.
Rhesus macaques. Ten healthy adult Macaca mulatta of
Chinese origin (3–6 kg) were used for this study. Brieﬂy, all
ten macaques were challenged by intramuscular (i.m.)
inoculation with 1,000 pfu of ZEBOV, strain Kikwit.
Approximately 20–30 min after ZEBOV challenge, eight of
the animals received an i.m. injection with a dose of 2 3 10
7
pfu of the VSVDG/ZEBOVGP vector expressing the ZEBOV
GP that was divided among four different anatomical
locations (right and left triceps and right and left caudal
thigh). Two animals served as experimental controls, of which
one received an equivalent dose of the VSVDG/MARVGP
vector expressing the MARV GP and the other the VSVDG/
LASVGPC vector expressing the Lassa virus glycoprotein
precursor by the same routes. All animals were checked twice
daily for clinical symptoms of ZEBOV HF using an established
score sheet. Swab samples (oral, nasal, rectal) and blood were
taken prior to ZEBOV challenge and on days 3, 6, and 10 post
ZEBOV challenge. Survivors were kept for more than 50 d. All
nonhuman primate studies were performed in BSL-4
biocontainment at United States Army Medical Research
Institute of Infectious Diseases (USAMRIID) and were
approved by the USAMRIID Laboratory Animal Care and
Use Committee. Animal research was conducted in compli-
ance with the Animal Welfare Act and other Federal statues
and regulations relating to animals; experiments involving
animals adhere to the principles stated in the Guide for the Care
and Use of Laboratory Animals, National Research Council, 1996.
The facility used is fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
International.
Haematology and Serum Biochemistry
Total white blood cell counts, lymphocyte counts, red
blood cell counts, platelet counts, haematocrit values, total
PLoS Pathogens | www.plospathogens.org January 2007 | Volume 3 | Issue 1 | e2 0055
Treatment of Ebola Infection
Author Summary
Being highly pathogenic for humans and monkeys and the subject
of former weapons programs makes Ebola virus one of the most
feared pathogens worldwide today. Due to a lack of licensed pre-
and post-exposure intervention, our current response depends on
rapid diagnostics, proper isolation procedures, and supportive care
of case patients. Consequently, the development of more specific
countermeasures is of high priority for the preparedness of many
nations. In this study, we investigated an attenuated vesicular
stomatitis virus expressing the Ebola virus surface glycoprotein,
which had previously demonstrated convincing efficacy as a vaccine
against Ebola infections in rodents and monkeys, for its potential
use in the treatment of an Ebola virus infection. Surprisingly,
treatment of guinea pigs and mice as late as 24 h after lethal Ebola
virus infection resulted in 50% and 100% survival, respectively. More
important, 50% of rhesus macaques (4/8) were protected if treated
20 to 30 min after Ebola virus infection. Currently, this approach
provides the most effective treatment strategy for Ebola infections
and seems particularly suited for the use in accidental exposures
and the control of human-to-human transmission during outbreaks.haemoglobin, mean cell volume, mean corpuscular volume,
and mean corpuscular haemoglobin concentration were
determined from nonhuman primate blood samples collected
in tubes containing EDTA, by using a laser-based haematol-
ogy analyzer (Beckman Coulter, http://www.beckmancoulter.
com). The white blood cell differentials were performed
manually on Wright-stained blood smears.
Virus Detection
RNA was isolated from nonhuman primate whole blood
and swabs using appropriate RNA isolation kits (Qiagen,
http://www1.qiagen.com). ZEBOV RNA was detected using
primer pairs targeting the L genes [ZEBOV: RT-PCR, nt
position 13344–13622; nested PCR, nt position 13397–13590].
The sensitivity of the ZEBOV-speciﬁc RT-PCR is approx-
imately 0.1 pfu/ml. ZEBOV titration was performed by plaque
assay on Vero E6 cells from all blood and selected organ
(adrenal, ovary, lymph nodes, liver, spleen, pancreas, lung,
heart, brain) and swab samples [23]. Brieﬂy, increasing 10-fold
dilutions of the samples were adsorbed to Vero E6 mono-
layers in duplicate wells (0.2 ml per well); thus, the limit for
detection was 25 pfu/ml.
Immune Responses
IgG and IgM antibodies against ZEBOV were detected with
an enzyme-linked immunosorbent assay (ELISA) using puri-
ﬁed virus particles as an antigen source [6]. Neutralization
assays were performed by measuring plaque reduction in a
constant virus:serum dilution format as previously described
[9,26]. Brieﬂy, a standard amount of ZEBOV (;100 pfu) was
incubated with serial 2-fold dilutions of the serum sample for
60 min. The mixture was used to inoculate Vero E6 cells for
60 min. Cells were overlayed with an agar medium, incubated
for 8 d, and plaques were counted 48 h after neutral red
staining. End point titres were determined by the dilution of
serum, which neutralized 50% of the plaques (PRNT50).
Cellular Immune Responses
Peripheral blood mononuclear cells were isolated from
rhesus macaque whole blood samples by separation over a
Ficoll gradient. Approximately 1 3 10
6 cells were stained for
cell surface markers, granzyme B, and viral antigen using
monoclonal antibodies. Staining procedures were performed
as previously described [27].
Results
To test the concept that the VSVDG/ZEBOVGP vaccine
may have utility as a post-exposure treatment for EBOV HF,
we investigated its efﬁcacy in two rodent models, mouse [25]
and guinea pig [24], and a rhesus macaque model [11].
Initially, we treated groups of ﬁve BALB/c mice with i.p.
injections of 2310
5 pfu of the VSVDG/ZEBOVGP vaccine 24
h prior to challenge or 30 min or 24 h post i.p. challenge with
a 1,000 LD50 of the mouse-adapted ZEBOV (MA-ZEBOV) [25].
The immunization dose chosen was relatively high consider-
ing that as little as 2 3 10
0 pfu still conferred complete
protection against the same challenge dose (unpublished
data). Animals were weighed every day and scored for clinical
symptoms (see Methods). Untreated control animals (naı ¨ve
controls) rapidly lost weight, developed severe clinical
symptoms, and died on day 6 post-challenge (Figures 1A
and S1A). Surprisingly, all treated mice survived independent
of the time of treatment (Figure 1A). Those animals treated
24 h prior to challenge did not show any clinical symptoms,
whereas animals treated post-challenge developed mild
clinical symptoms. With all protected groups, mild weight
loss was observed during the ﬁrst day post-challenge (Figure
S1) indicating virus replication prior to clearance and
survival.
Next, we treated three groups of guinea pigs (Hartley
strain; six animals per group) with i.p. injection of 2310
5 pfu
of the VSVDG/ZEBOVGP either 24 h before challenge or 1 or
24 h after challenge with 1,000 LD50 of the guinea pig-
adapted ZEBOV (GA-ZEBOV) [24]. Disease progression was
followed and measured as described for the mice. Untreated
guinea pigs (naı ¨ve controls) showed weight loss at day 5 post-
challenge progressing to death on days 7 to 9 (Figures 1B and
S1B). Unlike the mice, the treatment groups were not fully
protected (Figures 1 and S1). Two animals (33%) died from
the group treated 24 h prior to challenge; one (17%) and
three (50%) animals died from the groups treated 1 and 24 h
post-challenge, respectively (Figures 1B and S1B). In all cases,
Figure 1. Kaplan-Meier Survival Curves for Mice and Guinea Pigs Given
Post-Exposure Treatment for ZEBOV Infection
(A) Mice (groups of five animals) were infected with 1,000 LD50 of
MA-ZEBOV by i.p. injection. At various times points 24 h prior to
challenge (*), 30 min after challenge (¤), or 24 h after challenge (n) they
were treated with 23 10
5 pfu of VSVDG/ZEBOVGP by i.p. injection. The
controls (&) were left untreated and all died. All treated animals survived
the challenge.
(B) Guinea pigs (groups of six animals) were infected with 1,000 LD50 of
GA-ZEBOV by i.p. injection. At various times points 24 h prior to
challenge (*), 1 h after challenge (¤), or 24 h after challenge (n) they
were treated with 2 3 10
5 pfu of VSVDG/ZEBOVGP by i.p. injection. The
controls (&) were left untreated and all died.
doi:10.1371/journal.ppat.0030002.g001
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death, were signiﬁcantly delayed. All surviving animals lost
weight and became sick with a degree of severity that
correlated very well with disease outcome. The ﬁnal survival
rates were 66% for the pre-treatment group (24 h prior to
challenge) and 83% and 50% in the 1- and 24-h post-
treatment groups, respectively (Figures 1B and S1B).
Encouraged by the success in the rodent models, we treated
eight rhesus monkeys (subjects 1 to 8) with i.m. injections of
the VSVDG/ZEBOVGP vaccine (2 3 10
7 pfu), and two rhesus
monkeys (subjects c1 and c2) with VSV control vaccines (2 3
10
7 pfu) (see Methods) 20 to 30 min after challenge with 1,000
pfu of ZEBOV. The immunization and challenge doses were
equivalent to what had been used in previous successful pre-
exposure vaccine studies [6,9]. All animals became febrile by
day 6 and haematology data indicated evidence of illness by
day 6, usually manifested as lymphopenia, in most of these
animals (Table 1). Surprisingly, 50% of the VSVDG/ZE-
BOVGP-treated animals (subjects 1, 2, 5, and 7) survived the
lethal ZEBOV challenge (Figure 2A; Table 1) without showing
signs of severe disease, while three VSVDG/ZEBOVGP-treated
macaques (subjects 3, 4, and 8) developed characteristic
ZEBOV HF including fever, perturbations in clinical chem-
istry values, and macular rashes (Figure S2); these animals
died on days 9 (subject 3) and 10 (subjects 4 and 8) (Figure 2A;
Table 1). Notably, all VSVDG/ZEBOVGP-treated animals that
succumbed to the ZEBOV challenge (subjects 3, 4, and 8)
developed plasma viraemia on day 6 between 1310
4 and 13
10
6 pfu/ml, whereas plasma viraemia was transient in the
animals that survived (subjects 1, 2, 5, and 7) and did not
exceed 1310
2 pfu/ml on day 6 (Figure 2B). The ﬁnal VSVDG/
ZEBOVGP-treated macaque (subject 6) died on day 18 (Figure
2A; Table 1). This animal had a transient low-level ZEBOV
viraemia on day 6 and had cleared the ZEBOV infection by
day 10 (Figure 2B). Furthermore, the animal never developed
clinical symptoms consistent with severe ZEBOV HF, and
organ infectivity titration showed no evidence of infectious
ZEBOV in any of the tissues surveyed at post-mortem.
Pathology results showed that this macaque died from
disseminated septicaemia and peritonitis caused by Strepto-
coccus pneumoniae as demonstrated by immunohistochemistry
(unpublished data). The source of the bacterial infection is
unknown. Both monkeys treated with the VSV control vectors
(subjects c1 and c2) developed severe symptoms over the
disease course with plasma viraemia titres in excess of 1310
6
pfu/ml on day 6, macular rash (Figure S2) evident by day 7,
and death on day 8 after ZEBOV challenge (Figure 2A; Table
1) with peak viraemia titre of .1310
8 pfu/ml (Figure 2B). In
addition, all animals were also tested for VSV viraemia using
RT-PCR (unpublished data). In accordance with our previous
results [9,10], VSV RNA was detected in most immunized
animals only at day 3 post-immunization indicating transient
viraemia of the vaccine vector. There was no correlation
between VSV viraemia and survival.
All four animals that survived the ZEBOV challenge
(subjects 1, 2, 5, and 7), and the animal that survived until
Table 1. Clinical Findings
Animal Day
1–5
Day 6 Day 7–9 Day 10 Day 14 Day 22 Day of
Death
Subject 1 Fever, anorexia, lymphopenia,
thrombocytopenia, AST""
Anorexia Lymphopenia,
thrombocytopenia, ALT""",
AST""", BUN""", CRE""",
GGT"
Thrombocytopenia, AST" Survived
Subject 2 Fever Survived
Subject 3 Fever, anorexia, lymphopenia,
AST"
Moderate rash, anorexia NA NA Day 9
Subject 4 Fever, anorexia Moderate rash, anorexia NA NA Day 10
Subject 5 Fever, lymphopenia Anorexia Thrombocytopenia, GGT" GGT" Survived
Subject 6 Fever, lymphopenia Anorexia Anorexia, thrombocytopenia,
ALT",A S T ""
Anorexia, lymphopenia NA Day 18
Subject 7 Fever, lymphopenia Survived
Subject 8 Fever, anorexia, lymphopenia,
thrombocytopenia
Moderate rash, anorexia Severe rash, thrombocytopenia,
ALP",A L T """,A S T """, BUN""",
CRE", GGT""
NA NA Day 10
Control 1 Fever, mild rash, lymphopenia Moderate rash, anorexia,
thrombocytopenia, ALP",
ALT""",A S T """,B U N ",
CRE"", GGT""
NA NA NA Day 8
Control 2 Fever, lymphopenia, ALT",A S T " Severe rash, anorexia NA NA NA Day 8
Fever is defined as a temperature more than 2.5 8F over baseline or at least 1.5 8F over baseline and  103.5 8F.
Mild rash: focal areas of petechiae covering less than 10% of the skin; moderate rash: areas of petechiae covering between 10% and 40% of the skin; severe rash: areas of petechiae or
echymosis covering more than 40% of the skin.
Lymphopenia and thrombocytopenia defined by  35% drop in numbers of lymphocytes and platelets, respectively.
Phlebotomy was performed and rectal temperatures were recorded on days 3, 6, 10, 14, and 22 with the exception of control 1, where phlebotomy and rectal temperature were also taken
on day 8 at the time of euthanasia.
", 2- to 3-fold increase; "", 4- to 5-fold increase; """, .5-fold increase.
ALP, alkaline phosphatase, ALT, alanine aminotransferase or serum glutamic-pyruvic transaminase (sGPT); AST, aspartate aminotransferase or serum glutamic-oxaloacetic transaminase
(sGOT); BUN, blood urea nitrogen; CRE, creatinine; GGT, gamma-glutamyltransferase or gamma-glutamyl transpeptidase; NA, not applicable, as the animal had succumbed to EBOV
challenge.
doi:10.1371/journal.ppat.0030002.t001
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immune responses with low titre IgM antibodies detected on
days 6–14 (subjects 1, 5, and 7) (Figure 3A) and moderate IgG
antibody titres detected on days 10–22 (subjects 1, 2, 5, 6, and
7) (Figure 3B). Neutralizing antibody titres to ZEBOV (1:80)
were detected on days 14–37 after challenge in all four animals
that survived the ZEBOV challenge (subjects 1, 2, 5, and 7) and
the animal that survived until day 18 (subject 6) (Figure 3C).
Humoral immune responses could not be detected in any of
the non-survivors although these animals lived until day 9 and
10 post-challenge, which was sufﬁcient to mount detectable
IgM and IgG responses in the surviving animals.
We also evaluated changes in populations of peripheral
blood mononuclear cells during the course of the study to
identify any differences between the rhesus monkeys treated
with the VSVDG/ZEBOVGP vector and the controls. A rapid
loss of CD4
þ lymphocytes, CD8
þ lymphocytes, and NK cells
has been reported during ZEBOV infection of nonhuman
primates [28]. In this study, we also detected a decline in the
circulating CD4
þ and CD8
þ (2%–10% decrease) lymphocyte
populations on day 6 in most of the animals regardless of
treatment or outcome with a 7%–22% decrease and 2%–10%
decrease in cell numbers observed, respectively (Table 1).
However, the percentage of NK cells did not drop in any of
the animals treated with VSVDG/ZEBOVGP vector on day 6,
but markedly increased. Interestingly, a sharp decline in NK
cell number (10% decrease) was observed on day 10 in one of
the animals treated with the VSVDG/ZEBOVGP vector.
Similarly, a marked increase in B cells was noted for all
animals regardless of treatment or outcome on day 6,
followed by a decline in B cell number on day 10.
Figure 2. Survival and Plasma Viraemia for Rhesus Monkeys Given Post-
Exposure Treatment for ZEBOV Infection
(A) Kaplan-Meier survival curves for animals treated with ;2310
7 pfu of
VSVDG/ZEBOVGP (subjects 1 to 8, solid line) or VSV control vectors
(subjects c1 and c2, dotted line) 20–30 min after i.m. challenge with
1,000 pfu of ZEBOV.
(B) Plasma viraemia of animals treated with VSVDG/ZEBOVGP or VSV
control vectors 20–30 min after i.m. challenge with 1,000 pfu of ZEBOV.
Viraemia was determined by plaque assay at indicated time points. The
asterisk indicates that on day 8 post-challenge viraemia levels were only
determined for the control animals (subjects c1 and c2). Plasma viraemia
levels at day 6 post-ZEBOV challenge could be separated into three
different groups. Control animals, which received VSV control vectors
(black square), developed high plasma viraemias (.6 log10 pfu/ml).
Animals treated with VSVDG/ZEBOVGP, which developed fulminant
EBOV HF and succumbed to ZEBOV challenge (orange square),
developed moderate plasma viraemias (;4–6 log10 pfu/ml), while
animals treated with VSVDG/ZEBOVGP, which survived (green square),
had low plasma viraemias ( 1.4 log10 pfu/ml). Subject 6 did not develop
fulminant disease consistent with EBOV HF and succumbed on day 18
from a secondary bacterial infection.
doi:10.1371/journal.ppat.0030002.g002
Figure 3. Serological Response Profile for Rhesus Monkeys Given Post-
Exposure Treatment for ZEBOV Infection
IgM (A), IgG (B), and development of EBOV-neutralizing antibodies (C) in
sera of animals treated with 2 3 10
7 pfu of VSVDG/ZEBOVGP 20–30 min
after i.m. challenge with 1,000 pfu of ZEBOV.
doi:10.1371/journal.ppat.0030002.g003
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Although no EBOV vaccine is currently licensed for human
use, recent advances have been made and efﬁcacy studies in
nonhuman primates with several platforms have been
encouraging [6,7,9]. Far less progress has been made in
developing treatment interventions for EBOV infections
[5,13,14]. Thus, there is clearly a need to develop effective
strategies to respond to future EBOV outbreaks in Africa and
to counter acts of bioterrorism using EBOV. Additionally, the
potential EBOV exposure involving a researcher at a United
States Army laboratory [16] and the unfortunate death of a
Russian scientist after an accidental exposure to EBOV [15],
underscore the need for medical countermeasures for post-
exposure prophylaxis. Recently, a post-exposure strategy to
mitigate the coagulation disorders that typify ﬁloviral
infections improved survival from 0% to 33% in the rhesus
macaque model of ZEBOV HF [11]. Here, we show a
signiﬁcant advance in treating EBOV infections.
Our data clearly demonstrate the efﬁcacy of the VSV-based
EBOV vaccine vector in post-exposure treatment in three
relevant animal models. In the mouse model it was possible to
protect all animals following challenge with treatment as late
as 24 h post infection. It is known from previous data that
treatments and vaccines given to mice are more effective than
seen in guinea pigs and nonhuman primates [1,2,13].
However, in this case it was possible to protect over 50% of
guinea pigs and 50% of nonhuman primates from uniformly
lethal ZEBOV challenge. It should be noted that mice
received about 10 or 100 times more vaccine per weight than
guinea pigs and nonhuman primates, respectively. Thus, it is
possible that further optimization of dosing strategies could
improve the results.
The rhesus macaques that survived infection all controlled
the virus within the ﬁrst 6 d of infection. The data clearly
show that moderate or high-level viraemia on day 6 invariably
resulted in a fatal outcome (Figure 2). In the current study, we
can conclude that neutralizing antibodies were not essential
for infection control (Figure 3) since they were not detected
until after the animals had cleared the EBOV infection.
Circulating CD4
þ and CD8
þ T cells were reduced in number
in all animals regardless of treatment (Table 1); this indicates
that the initial control of infection may not require classical
T-cell responses. The time course for EBOV HF in rhesus
macaques is very short (;8 d) and therefore, CD8
þ cytotoxic
T-cell responses are very unlikely to be involved in the
control of the infection because the cell numbers of speciﬁc
responding cells could not have peaked until after the
infection was controlled. The primary immune correlate of
protection seems to be the rapid development of non-
neutralizing antibody that was only seen in the protected
animals (Figure 3). This, coupled with the NK-cell increase in
the VSVDG/ZEBOVGP-treated animals, may have resulted in
signiﬁcantly enhanced killing of virus-infected primary target
cells and, consequently, elimination of the ZEBOV infection.
An important role of NK cells for protection has also been
described for immunization with virus-like particles [29].
Clearly, the adaptive response is essential to promote
survival as animals immunized with the control VSV-based
vaccines succumbed to the ZEBOV challenge (Figure 2, Table
1). Both control animals died on day 8, which is the historical
mean for rhesus monkeys infected by the same route and dose
with this seed stock (historical n ¼ 23). However, other
mechanisms probably contribute as well. Recently, Noble and
colleagues described a new paradigm for an interfering
vaccine in which one of the antiviral mechanisms of action is
intracellular interference with the replication of the lethal
wild-type virus [30]. In the current study, the VSV vectors
exploit the EBOV GP, which largely determines host cell
tropism and mediates viral entry [31]. We have demonstrated
that the VSV vectors expressing the ZEBOV GP will infect the
same cells as wild-type ZEBOV in vitro [8]. Also, the VSVDG/
ZEBOVGP vectors replicate signiﬁcantly faster than wild-type
ZEBOV [8]. Therefore, it is possible that these vectors
compete with ZEBOV through viral interference. Clearly,
even mild to moderate inhibition of ZEBOV replication may
delay the course of infection and tip the balance in the favor
of the host.
VSV has been shown to be a potent inducer of the innate
and adaptive immune system [32–34]. In contrast, EBOV has
acquired mechanisms to counteract the innate immune
responses of the host at different levels [1,2,35]. The virion
protein (VP) 35 of ZEBOV functions as an inhibitor of type I
interferon production by blocking the activation of IRF-3
[36–38]. In addition to VP35, the ZEBOV protein VP24
functions as an inhibitor of type I interferon signaling by
blocking nuclear accumulation of activated STAT-1 [35,39].
Recently, it was suggested that VP24 blocks the downstream
signaling cascades activated by type I interferon by inhibiting
the phosphorylation of p38 [40]. Therefore, treatment with
the VSV vectors might induce or boost the innate immune
response in the host, and thus, counteract the immune
inhibitory effect of EBOV. In this case, the host will mount a
nonspeciﬁc innate immune response allowing for time to
develop a speciﬁc adaptive response that can overcome the
EBOV infection and again tip the balance in favor of survival
of the host.
In a historical context, it is important to note that the
mechanism for post-exposure protection of humans against
smallpox and rabies are also not fully understood. For post-
exposure treatment of rabies, levels of neutralizing antibodies
have been used as a measure of protection. However, several
studies of HIV-infected patients with likely or proven
exposure to rabies showed that these patients failed to
develop neutralizing antibodies after post-exposure rabies
vaccination, yet there were no reports of death of these
patients attributed to rabies [41,42]. Moreover, studies in
mice suggest that cell-mediated immunity may play an
essential role in post-exposure protection [43]. In the case
of smallpox, post-exposure protection is presumed to be due
in part to differences in the route of exposure and growth
kinetics of the wild-type variola virus versus the vaccinia
vaccine [20]. Brieﬂy, infection with variola usually starts in the
upper and lower respiratory tract with subsequent spread to
lymphoid tissues. Thus, the natural variola infection proceeds
much slower than post-exposure i.m. vaccinia vaccination,
which bypasses the respiratory tract infection. In addition, it
appears that vaccinia has a shorter incubation period than
variola virus resulting in a more rapid development of cell-
mediated immunity and neutralizing antibody. However, a
recent study using monkeypox in the macaque model
demonstrated better results with antiviral therapy than
post-exposure vaccination [44].
Post-exposure treatment with the VSV-based MARV
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Treatment of Ebola Infectionvaccine vector against MARV challenge was more potent and
resulted in complete survival, no disease, and undetectable
viraemia [12]. The development of symptoms and viraemia in
MARV-infected rhesus monkeys is delayed compared with
ZEBOV [12,45], which may explain the difference in efﬁcacy
in post-exposure treatment with the VSV-based vectors. The
efﬁcacy of the VSV-based EBOV vector in post-exposure
treatment might be increased by a higher treatment dose or
multiple treatments over a longer period of time as is being
done in post-exposure treatment of rabies [46]. Alternatively,
combination therapy should be considered to increase
therapeutic efﬁcacy. In the case of EBOV, post-exposure
treatment with the VSV-based EBOV vector could be
combined with the previously published post-exposure
strategy to mitigate the coagulation disorders [11].
Nevertheless, the VSV-based ZEBOV vaccine currently
provides the most effective and promising single treatment
strategy for EBOV HF. It is likely that the mechanism of
protection by the VSV-based vaccine is multifactorial; while
NK cells and antibody responses appear to be important to
survival, viral interference and innate immune response are
almost certainly essential in delaying the progression of the
ZEBOV infection and extending the window for the adaptive
response to become functional.
Post-exposure treatment is particularly suited for use in
accidentally exposed individuals and in the control of
secondary transmission during naturally occurring outbreaks
or deliberate releases. Our results also suggest that this VSV
platform might be even more beneﬁcial as a fast-acting
single-shot preventive vaccine. Finally, this system also
provides an excellent opportunity to study the fundamental
mechanisms that lead to such devastating disease following
infection with ZEBOV.
Supporting Information
Figure S1. Weight Loss of Mice and Guinea Pigs Given Post-Exposure
Treatment for ZEBOV Infection
(A) Mice (groups of ﬁve animals) were infected with 1,000 LD50 of
MA-ZEBOV by i.p. injection. At various times points 24 h prior to
challenge (*), 30 min after challenge (¤), or 24 h after challenge (n)
they were treated with 2 310
5 pfu of VSVDG/ZEBOVGP by i.p.
injection. The controls (&) were left untreated and all died. All treated
animals survived the challenge.
(B) Guinea pigs (groups of six animals) were infected with 1,000 LD50
of GA-ZEBOV by i.p. injection. At various times points 24 h prior to
challenge (*), 1 h after challenge (¤), or 24 h after challenge (n) they
were treated with 2 310
5 pfu of VSVDG/ZEBOVGP by i.p. injection.
The controls (&) were left untreated and all died. , animals that
succumbed to infection in the treated groups.
Found at doi:10.1371/journal.ppat.0030002.sg001 (980 KB TIF)
Figure S2. Clinical Symptoms
Macular rash covering the inguinal region and inner leg of a VSVDG/
ZEBOVGP-treated macaque (subject 8) that succumbed 10 d after
ZEBOV challenge.
Found at doi:10.1371/journal.ppat.0030002.sg002 (5.1 MB TIF)
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession num-
ber for the ZEBOV Mayinga strain is AF272001; the accession number
for the MARV Musoke strain is Z12132.
Acknowledgments
The authors thank Daryl Dick and Andrea Paille from the National
Microbiology Laboratory of the Public Health Agency of Canada for
technical assistance in biocontainment and animal care. From United
States Army Medical Research Institute of Infectious Diseases, the
authors thank Denise Braun for technical assistance and Tom Larsen
for diagnostic pathology. We also thank Peter Jahrling for helpful
discussions. We thank John Rose (Yale University) for kindly
providing us with the vesicular stomatitis virus reverse genetics
system. Opinions, interpretations, conclusions, and recommenda-
tions are those of the authors and are not necessarily endorsed by the
United States Army.
Author contributions. HF, SMJ, US, MB, LEH, and TWG conceived
and designed the experiments. HF, SMJ, KMDD, JBG, AG, EAF, LF,
FF, LEH, and TWG performed the experiments. HF, SMJ, KMDD,
JBG, US, AG, MB, EAF, LF, FF, LEH, and TWG analyzed the data. HF,
SMJ, KMDD, JBG, US, AG, MB, EAF, LF, FF, LEH, and TWG
contributed reagents/materials/analysis tools. HF, SMJ, and TWG
wrote the paper.
Funding. Work on ﬁloviruses at the National Microbiology
Laboratory was supported by the Public Health Agency of Canada,
a grant awarded to HF from the Canadian Institutes of Health
Research (MOP-43921), and a grant awarded to SMJ from Chemical,
Biological, Radiological, and Nuclear (CBRN) Research and Technol-
ogy Initiative (CRTI). Work on ﬁloviruses at USAMRIID was
supported by the Medical Chemical/Biological Defense Research
Program and Military Infectious Diseases Research Program, United
States Army Medical Research and Materiel Command (project
number 02-4-4J-081 and 04-4-7J-012).
Competing interests. The authors have declared that no competing
interests exist.
References
1. Feldmann H, Jones S, Klenk HD, Schnittler HJ (2003) Ebola virus: From
discovery to vaccine. Nat Rev Immunol 3: 677–685.
2. Geisbert TW, Jahrling PB (2004) Exotic emerging viral diseases: Progress
and challenges. Nat Med 10: 110–121.
3. Sanchez A, Khan AS, Zaki SR, Nabel GJ, Ksiazek TG, et al. (2001)
Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editors.
Fields virology. 4th edition. Philadelphia: Lippincott Williams and Wilkins.
pp. 1279–1304.
4. Walsh PD, Abernethy KA, Bermejo M, Beyers R, De Wachter P, et al. (2003)
Catastrophic ape decline in western equatorial Africa. Nature 422: 611–
614.
5. Feldmann H, Jones SM, Schnittler HJ, Geisbert T (2005) Therapy and
prophylaxis of Ebola virus infections. Curr Opin Investig Drugs 6: 823–830.
6. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, et al. (2003)
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human
primates. Nature 424: 681–684.
7. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ (2000) Development
of a preventive vaccine for Ebola virus infection in primates. Nature 408:
605–609.
8. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, et al. (2004)
Properties of replication-competent vesicular stomatitis virus vectors
expressing glycoproteins of ﬁloviruses and arenaviruses. J Virol 78: 5458–
5465.
9. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, et al. (2005)
Live-attenuated recombinant vaccine protects nonhuman primates against
Ebola and Marburg viruses. Nat Med 11: 786–790.
10. Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, et al. (2005)
Development of a new vaccine for the prevention of Lassa fever. PLoS Med
2: e183. doi:10.1371/journal.pmed.0020183
11. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, et al. (2003)
Treatment of Ebola virus infection with a recombinant inhibitor of factor
VIIa/tissue factor: A study in rhesus monkeys. Lancet 362: 1953–1958.
12. Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, et
al. (2006) Post-exposure protection against Marburg haemorrhagic fever
with recombinant vesicular stomatitis virus vectors in non-human
primates: An efﬁcacy assessment. Lancet 367: 1399–1404.
13. Bray M, Paragas J (2002) Experimental therapy of ﬁlovirus infections.
Antiviral Res 54: 1–17.
14. Geisbert TW, Hensley LE (2004) Ebola virus: New insights into disease
aetiopathology and possible therapeutic interventions. Expert Rev Mol
Med 6: 1–24.
15. ProMED-mail (2004) Ebola, lab accident death: Russia (Siberia). Archive
number 20040522.1377.
16. ProMED-mail. USA (MD) (2004) Ebola virus, laboratory accident. Archive
number 200405220.0550.
17. Rupprecht CE, Gibbons RV (2004) Clinical practice. Prophylaxis against
rabies. N Engl J Med 351: 2626–2635.
PLoS Pathogens | www.plospathogens.org January 2007 | Volume 3 | Issue 1 | e2 0060
Treatment of Ebola Infection18. Rupprecht CE, Hanlon CA, Hemachudha T (2002) Rabies re-examined.
Lancet Infect Dis 2: 327–343.
19. Yu AS, Cheung RC, Keeffe EB (2004) Hepatitis B vaccines. Clin Liver Dis 8:
283–300.
20. Massoudi MS, Barker L, Schwartz B (2003) Effectiveness of post-exposure
vaccination for the prevention of smallpox: Results of a Delphi analysis. J
Infect Dis 188: 973–976.
21. Mortimer PP (2003) Can post-exposure vaccinations against smallpox
succeed? Clin Infect Dis 36: 622–629.
22. Schnell MJ, Buonocore L, Kretzschmar E, Johnson E, Rose JK (1996) Foreign
glycoproteins expressed from recombinant vesicular stomatitis viruses are
incorporated efﬁciently into virus particles. Proc Natl Acad Sci U S A 93:
11359–11365.
23. Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, et al. (1999)
Evaluation of immune globulin and recombinant interferon-alpha2b for
treatment of experimental Ebola virus infections. J Infect Dis 179 (Suppl 1):
224–234.
24. Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, et al. (1999)
Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect
Dis 179 (Suppl 1): 203–217.
25. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J (1998) A mouse
model for evaluation of prophylaxis and therapy of Ebola hemorrhagic
fever. J Infect Dis 178: 651–661.
26. Jahrling PB (1999) Filoviruses and arenaviruses. In: Murray PR, editor.
Manual of clinical microbiology. Washington (D. C.): ASM Press. pp. 1125–
1136.
27. Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW (2004)
Depletion of peripheral blood T lymphocytes and NK cells during the
course of Ebola hemorrhagic fever in cynomolgus macaques. Viral
Immunol 17: 390–400.
28. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, et al. (2003)
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques:
Evidence that dendritic cells are early and sustained targets of infection.
Am J Pathol 163: 2347–2370.
29. Warﬁeld KL, Perkins JG, Swenson DL, Deal EM, Bosio CM, et al. (2004) Role
of natural killer in innate protection against lethal Ebola virus infection. J
Ex Med 200: 169–179.
30. Noble S, McLain L, Dimmock NJ (2004) Interfering vaccine: A novel
antiviral that converts a potentially virulent infection into one that is
subclinical and immunizing. Vaccine 22: 3018–3025.
31. Feldmann H, Volchkov VE, Volchkova VA, Stroher U, Klenk HD (2001)
Biosynthesis and role of ﬁloviral glycoproteins. J Gen Virol 82: 2839–2848.
32. Roberts A, Buonocore L, Price R, Forman J, Rose JK (1999) Attenuated
vesicular stomatitis viruses as vaccine vectors. J Virol 73: 3723–3732.
33. Roberts A, Kretzschmar E, Perkins AS, Forman J, Price R, et al. (1998)
Vaccination with a recombinant vesicular stomatitis virus expressing an
inﬂuenza virus hemagglutinin provides complete protection from inﬂuenza
virus challenge. J Virol 72: 4704–4711.
34. Zinkernagel RM, Adler B, Holland JJ (1978) Cell-mediated immunity to
vesicular stomatitis virus infections in mice. Exp Cell Biol 46: 53–70.
35. Basler CF, Palese P (2004) Modulation of innate immunity by ﬁloviruses. In:
Klenk HD, Feldmann H, editors. Ebola and Marburg viruses: Moelcular and
cellular biology. Wymondham (United Kingdom): Horizon Bioscience. pp.
305–349.
36. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E, et al.
(2003) The Ebola virus VP35 protein inhibits activation of interferon
regulatory factor 3. J Virol 77: 7945–7956.
37. Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J, et al. (2000) The
Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl
Acad Sci U S A 97: 12289–12294.
38. Hartman AL, Towner JS, Nichol ST (2004) A C-terminal basic amino acid
motif of Zaire Ebola virus VP35 is essential for type I interferon
antagonism and displays high identity with the RNA-binding domain of
another interferon antagonist, the NS1 protein of inﬂuenza A virus.
Virology 328: 177–184.
39. Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, et al. (2006) Ebola
virus VP24 binds karyopherin falphag1 and blocks STAT1 nuclear
accumulation. J Virol 80: 5156–5167.
40. Halfmann PJ, Kawaoka Y (2005) Ebola VP24 inhibits type I interferon
signaling. XIII International Congress of Virology. San Francisco.
41. Jaijaroensup W, Tantawichien T, Khawplod P, Tepsumethanon S, Wilde H
(1999) Post-exposure rabies vaccination in patients infected with human
immunodeﬁciency virus. Clin Infect Dis 28: 913–914.
42. Tantawichien T, Jaijaroensup W, Khawplod P, Sitprija V (2001) Failure of
multiple-site intradermal post-exposure rabies vaccination in patients with
human immunodeﬁciency virus with low CD4þ T lymphocyte counts. Clin
Infect Dis 33: E122–E124.
43. Mifune K, Takeuchi E, Napiorkowski PA, Yamada A, Sakamoto K (1981)
Essential role of T cells in the post-exposure prophylaxis of rabies in mice.
Microbiol Immunol 25: 895–904.
44. Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, et al.
(2006) Antiviral treatment is more effective than smallpox vaccination
upon lethal monkeypox virus infection. Nature 439: 745–748.
45. Johnson ED, Johnson BK, Silverstein D, Tukei P, Geisbert TW, et al. (1996)
Characterization of a new Marburg virus isolated from a 1987 fatal case in
Kenya. Arch Virol Suppl 11: 101–114.
46. Dreesen DW, Hanlon CA (1998) Current recommendations for the
prophylaxis and treatment of rabies. Drugs 56: 801–809.
PLoS Pathogens | www.plospathogens.org January 2007 | Volume 3 | Issue 1 | e2 0061
Treatment of Ebola Infection